MOHW postponed NHI coverage suspension for efficacy unproven drugs.

Published: 2001-10-30 07:00:00

Updated: 2001-10-30 07:00:00

The MOHW announced on Oct. 24 that the NHI payment rejection plan for the drugs that were not completed with their efficacy equivalent tests starting from Nov. 1 this year would put off until May next year.

Earlier on May 7 the MOHW changed the NHI medication payment system including the upper...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK